Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study. - Wikidata - awgldk - TriplyDB

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

http://www.wikidata.org/entity/Q37672806

about

Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

http://www.wikidata.org/entity/Q37672806

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effectiveness and metabolic co ...... Thailand: A prospective study.

@en

Effectiveness and metabolic co ...... Thailand: A prospective study.

@nl

type

label

Effectiveness and metabolic co ...... Thailand: A prospective study.

@en

Effectiveness and metabolic co ...... Thailand: A prospective study.

@nl

prefLabel

Effectiveness and metabolic co ...... Thailand: A prospective study.

@en

Effectiveness and metabolic co ...... Thailand: A prospective study.

@nl

P1433

Q37672806-DC6D14AF-5254-4F32-92E8-D82EA1E9806A

P1476

Q37672806-069D3ED4-4045-4240-BD8E-5FE833A19F46

P2093

Q37672806-3EF8A486-715B-4D5B-ADFE-666FC4FA49BB

Q37672806-49D62732-3452-4649-98FA-6E92A888FD9A

Q37672806-6DCCF22C-1EEA-46A2-8991-8BD59FD8F0C1

Q37672806-96047F2D-F67B-46B3-972F-E62FAD1E973B

Q37672806-CD80C85D-7CEA-44D1-8ED1-5DC0D2E32FAD

Q37672806-DFCE2E52-9FAB-4BE4-ACB0-E1CA34F5FEB7

P2860

Q37672806-0E68FC65-A1FA-41FD-9B28-2EB289D16457

Q37672806-15E111BE-470B-4C68-A4DA-B51EE98392C8

Q37672806-2CCDC77A-3D1F-4B7F-8253-2805C3336BCD

Q37672806-3E7871BC-74B1-4FA2-BF89-C558A9FB29CA

Q37672806-400F02EE-33A0-426E-BD01-0A3766586D2A

Q37672806-594DEC79-7191-4EB6-8205-5B091C87180C

Q37672806-594E6726-34C9-4793-8EF4-DC080B68EFB8

Q37672806-5F134E9E-3824-42F5-A8A0-6852BB38CB80

Q37672806-648737E7-91EC-4809-BBD5-EED5101D1EDC

Q37672806-6B4C52E1-47C9-4730-8FBF-403806464F04

P304

Q37672806-EC92F8C4-0148-4BD9-A1E8-24EA42DA3945

P31

Q37672806-CB8A378E-4B3D-4F94-A56F-0A8204CBF677

P356

Q37672806-EBF5A84C-4742-4665-B924-8669BFFF4324

P433

Q37672806-3A42B8E2-92C7-453B-A3DE-148ACFEC44E7

P478

Q37672806-25CC9677-9992-4D2B-AF24-2245AB840033

P50

Q37672806-02F380AF-F49E-455F-8AB9-50BD3FFA6344

P577

Q37672806-9601BE2A-8977-497E-991F-74CAE709AE95

P5875

Q37672806-5D441B34-85F2-4141-9DDF-3F359B055B52

P698

Q37672806-4FB0DA81-2019-4436-8372-D376FF0B20FF

P921

Q37672806-55DEDE68-1BA5-43E6-A0B0-1F0EACBF6E54

Q37672806-5AE1BAD8-D36B-42F6-82BE-60B6603FDD70

P932

Q37672806-48709072-6A43-485F-BD6C-6C0CCFA7A51C

P356

J.CURTHERES.2008.02.007

P1433

Current Therapeutic Research

P1476

Effectiveness and metabolic co ...... Thailand: A prospective study.

@en

P2093

Achara Chaovavanich

http://www.w3.org/2001/XMLSchema#string

Chatiya Athichathanabadi

http://www.w3.org/2001/XMLSchema#string

Sirirat Likanonsakul

http://www.w3.org/2001/XMLSchema#string

Somsit Tansuphaswadikul

http://www.w3.org/2001/XMLSchema#string

Weerawat Manosuthi

http://www.w3.org/2001/XMLSchema#string

Wisit Prasithsirikul

http://www.w3.org/2001/XMLSchema#string

P2860

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

Sex differences in nevirapine rash.

Update on HIV/AIDS in Thailand.

Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.

A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V

The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.

Clinical experience with non-nucleoside reverse transcriptase inhibitors.

Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs.

Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.

P304

90-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CURTHERES.2008.02.007

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Somnuek Sungkanuparph

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237716300

http://www.w3.org/2001/XMLSchema#string

P698

24692786

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3969962

http://www.w3.org/2001/XMLSchema#string